Jakarta - In accordance with the direction of national policies and strategies 2015-2019, increasing the competitiveness of the pharmaceutical and medical device industry, national resilience and independence, must be strengthened by developing a competitive domestic pharmaceutical and medical device industry, among others through regulations that favor domestic industries, strengthening domestic industries and increasing the use of domestic products, increasing resources, availability of raw materials, Health Technology Assessments (HTA), Health Technology Management (HTM), research and development of pharmaceuticals and medical devices that meet standards.

The Pharmaceutical and Medical Devices Program seeks to improve access, independence, and quality of pharmaceutical preparations and medical devices for health development. One form of effort to increase access, independence, and quality is through information dissemination, advocacy, and facilitation across stakeholders, with this activity it is hoped that cross-program, cross-sector, and related partners can obtain the latest information in the field of pharmaceuticals and medical devices, and collaborate on various inputs.

To achieve the above objectives and in order to face the 2015 ASEAN Economic Community which has been running, especially in the health equipment sector, a “Pharmaceutical and Health Equipment Seminar” was held with the theme “The 1st Technofarmalkes 2019: Indonesia Health Tech Innovation” on September 10 to 11, 2019.

This activity is also a step to develop innovation and competitiveness of domestic products including pharmaceutical products and medical devices, innovative research results, and bilateral, regional and international trade policy instruments; Medical device clinical trials; and facilitation (business matching, sharing experience) academics-business-government-community-innovators (A-B-G-C-I). Through the dissemination of innovation information, increasing competitiveness, financing, and health services to relevant stakeholders and encouraging the independence of pharmaceutical preparations and domestically produced medical devices.

The beneficiaries of this activity are academics, researchers, and innovation holders, domestic pharmaceutical and medical device industries and manufacturers, practitioners in health care facilities, and related stakeholders.